SELP: P-selectin
Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes.
- Drugs that act on it: 4
- Approved: 1
- In phases 1 to 3: 3
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on SELP, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
- Antibody 2
- Other 1
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- GlycoMimetics Incorporated125%
- Novartis Pharmaceuticals125%
- Roche125%
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| CrizanlizumabWithdrawn | Approved | Novartis Pharmaceuticals | Antibody | BlockerP-selectin blocker | 5 |
| Inclacumab | Phase 3 | Roche | Antibody | AntagonistP-selectin antagonist | 0 |
| Rivipansel | Phase 3 | GlycoMimetics Incorporated | Small molecule | AntagonistP-selectin antagonist | 0 |
| RG-1512 | Phase 2 | — | Other | InhibitorP-selectin inhibitor | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 5 in all, from ClinicalTrials.gov.| A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) | Crizanlizumab | Phase 3 | Recruiting | Novartis Pharmaceuticals | Jun 3, 2024 |
| Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases | Crizanlizumab | Phase 2 | Recruiting | Sheba Medical Center | Jun 18, 2023 |
| Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia | Crizanlizumab | Phase 1 / Phase 2 | Not yet recruiting | Children's Hospital Los Angeles | Jul 22, 2022 |
| Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study | Crizanlizumab | Phase 4 | Recruiting | Novartis Pharmaceuticals | Dec 8, 2020 |
| Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients | Crizanlizumab | Phase 3 | Active, not recruiting | Novartis Pharmaceuticals | Jan 24, 2019 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Deep vein thrombosis
- 0.30
- Thromboembolism
- 0.30
- Thrombophilia
- 0.30
- Asthma
- 0.29
- Aging
- 0.29
- Premature coronary artery atherosclerosis
- 0.26
- Abnormality of the skeletal system
- 0.25
- Viral pneumonia
- 0.19
- COVID-19
- 0.13
- Neoplasm
- 0.12
Genes and related targets
Complexes and families that share a gene with this target- Genes
- SELP
- Related
- Selectin
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5378, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P16109, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets